World Library  
My Account |  Register |  Help  
  
Flag as Inappropriate
Email this Article

Mmai

Article Id: WHEBN0022625451
Reproduction Date:

Title: Mmai  
Author: World Heritage Encyclopedia
Language: English
Subject: 6-Methyl-MDA, 5-HT1A receptor, RS-56812, MPPF, BRL-54443
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Mmai

MMAI
Systematic (IUPAC) name
5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
Chemical data
Formula C11H15NO 
Mol. mass 177.242 g/mol

5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University.[1] It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans.[1][2][3] It has been sold as a designer drug and research chemical online since 2010.[4]

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline,[5] and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).[6]

See also

References

  1. ^ a b Marona-Lewicka D, Nichols DE. (1994). "Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan". Eur J Pharmacol. 258 (1-2): 1–13.  
  2. ^ Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD. (1996). "Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA)". J Pharmacol Exp Ther. 279 (3): 1261–1267.  
  3. ^ Rudnick G, Wall SC. (1993). "Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters". Mol Pharmacol. 43 (2): 271–276.  
  4. ^ "Latest Research Chemicals". 
  5. ^ Marona-Lewicka D, Nichols DE. (1997). "The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats". Stress 2 (2): 91–100.  
  6. ^ Neuropharmacology; Silveira, R; Nichols, DE; Reyes-Parada, M (1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action". Neuropharmacology 38 (7): 1055–1061.  


Phenylalkylamines
Cyclized phenyl-
alkylamines
Tryptamines
Others
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.